文献速递妇科

上皮性卵巢癌中KANSL1作为免疫应答与HDAC抑制的生物标志物及靶基因

Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition.
PubMed 文献 · Gynecol Oncol · 2020-11-20

本研究利用170例卵巢肿瘤的表达微阵列和5年生存数据及45株卵巢癌细胞系的aCGH数据,寻找与预后相关的基因。发现196个基因表达与生存显著相关,其中82个与拷贝数变异相关;3个免疫应答基因聚集于6p21.3且与KANSL1表达负相关。KANSL1在卵巢癌中扩增/重排,与淋巴细胞谱相关,并可能是HDAC抑制应答的生物标志物。

要点

  • 196个基因表达与卵巢癌生存显著相关,82个与拷贝数变异相关。
  • 3个免疫应答基因聚集于表观遗传修饰的6p21.3,与KANSL1表达负相关。
  • KANSL1扩增/重排与淋巴细胞谱及HDAC抑制应答相关。

核心结论

  • 本研究鉴定出82个在卵巢癌中具有预后相关性及基因组改变的基因。
  • 免疫应答基因表达相关且与5年生存相关。
  • KANSL1可能是改变6p21.3免疫应答基因表达的主效基因并驱动HDAC抑制剂应答。

研究设计与样本

  • 使用170例卵巢肿瘤的表达微阵列和5年生存数据。
  • 使用45株卵巢癌细胞系的aCGH数据。
  • 通过搜索全基因组关联研究鉴定KANSL1中与免疫谱改变相关的遗传变异。
  • 研究KANSL1扩增/重排细胞系对HDAC抑制的敏感性。

主要发现

  • 196个基因的表达与生存统计学显著相关。
  • 82个基因的表达水平与拷贝数变异相关。
  • 3个免疫应答基因(HCP5、PSMB8、PSMB9)聚集于表观遗传修饰的染色体6p21.3。
  • 上述3个基因表达与表观遗传修饰基因KANSL1呈负相关。
  • KANSL1在卵巢癌中扩增/重排,与淋巴细胞谱相关,是HDAC抑制应答的生物标志物。

临床怎么用

  • KANSL1扩增/重排可能作为HDAC抑制治疗的潜在生物标志物。
  • KANSL1可能成为改善卵巢癌免疫谱及免疫治疗应答的靶点。
  • 未来需研究靶向KANSL1是否改变卵巢癌免疫谱并改善生存、HDAC抑制和/或免疫治疗应答。

局限性

  • 研究基于细胞系和肿瘤样本的回顾性分析,需进一步功能验证。
  • KANSL1作为主效基因的机制尚未完全阐明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: There is an immunoreactive subtype of ovarian cancer with a favorable prognosis, but the majority of ovarian cancers have limited immune reactivity. The reason for this is poorly understood. This study aimed to approach this question by identifying prognostically relevant genes whose prognostic mRNA expression levels correlated with a genomic event. METHODS: Expression microarray and 5-year survival data on 170 ovarian tumors and aCGH data on 45 ovarian cancer cell lines were used to identify amplified/deleted genes associated with prognosis. Three immune-response genes were identified mapping to epigenetically modified chromosome 6p21.3. Genes were searched for roles in epigenetic modification, identifying KANSL1. Genome-wide association studies were searched to identify genetic variants in KANSL1 associated with altered immune profile. Sensitivity to HDAC inhibition in cell lines with KANSL1 amplification/rearrangement was studied. RESULTS: Expression of 196 genes was statistically significantly associated with survival, and expression levels correlated with copy number variations for 82 of them. Among these, 3 immune-response genes (HCP5, PSMB8, PSMB9) clustered together at epigenetically modified chromosome 6p21.3 and their expression was inversely correlated to epigenetic modification gene KANSL1. KANSL1 is amplified/rearranged in ovarian cancer, associated with lymphocyte profile, a biomarker for response to HDAC inhibition, and may drive expression of immune-response genes. CONCLUSION: This study identifies 82 genes with prognostic relevance and genomic alteration in ovarian cancer. Among these, immune-response genes have correlated expression which is associated with 5-year survival. KANSL1 may be a master gene altering immune-response gene expression at 6p21.3 and drive response to HDAC inhibitors. Future research should investigate KANSL1 and determine whether targeting it alters the immune profile of ovarian cancer and improves survival, HDAC inhibition, and/or immunotherapy response.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Fejzo MS, Chen HW, Anderson L, et al. Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition. Gynecol Oncol. 2020. PMID: 33229045. doi:10.1016/j.ygyno.2020.11.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。